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Abstract
OBJECTIVES: In a multicentre, randomized-controlled, phase III trial in complex cardiovascular surgery (Randomized Evaluation of
Fibrinogen vs Placebo in Complex Cardiovascular Surgery: REPLACE), single-dose human fibrinogen concentrate (FCH) was associated
with the transfusion of increased allogeneic blood products (ABPs) versus placebo. Post hoc analyses were performed to identify possible
reasons for this result.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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METHODS: We stratified REPLACE results by adherence to the transfusion algorithm, pretreatment fibrinogen level (<_2 g/l vs >2 g/l) and
whether patients were among the first 3 treated at their centre.
RESULTS: Patients whose treatment was adherent with the transfusion algorithm [FCH, n = 47 (60.3%); placebo, n = 57 (77.0%); P = 0.036]
received smaller quantities of ABPs than those with non-adherent treatment (P < 0.001). Among treatment-adherent patients with pretreat-
ment plasma fibrinogen <_2 g/l, greater reduction in 5-min bleeding mass was seen with FCH versus placebo (median -22.5 g vs -15.5 g;
P = 0.071). Considering patients with the above conditions and not among the first 3 treated at their centre (FCH, n = 15; placebo, n = 22),
FCH was associated with trends towards reduced transfusion of ABPs (median 2.0 vs 4.0 units; P = 0.573) and greater reduction in 5-min
bleeding mass (median -21.0 g vs -9.5 g; P = 0.173). Differences from a preceding single-centre phase II study with positive outcomes in-
cluded more patients with pretreatment fibrinogen >2 g/l and fewer patients undergoing thoracoabdominal aortic aneurysm repair.
CONCLUSIONS: None of the patient stratifications provided a clear explanation for the lack of efficacy seen for FCH in the REPLACE trial
versus the positive phase II outcomes. However, together, the 3 factors demonstrated trends favouring FCH. Less familiarity with the proto-
col and procedures and unavoidable differences in the study populations may explain the differences seen between the phase II study and
REPLACE.
Clinical trial registration: NCT01475669 https://clinicaltrials.gov/ct2/show/NCT01475669; EudraCT trial no: 2011-002685-20.
Keywords: Blood coagulation • Cardiovascular surgical procedures • Fibrinogen • Haemorrhage
INTRODUCTION
Bleeding after cardiac surgery is commonly managed with alloge-
neic blood product (ABP) transfusion [1]. Complications after sur-
gery may be caused by continued bleeding, and/or ABP
transfusion (e.g. volume overload) [2, 3]. Using coagulation factor
concentrates instead of ABPs may enable lower infusion volumes,
more rapid infusion, higher peak concentration levels, and
reduced risk of pathogen transmission or exposure to antigens
[4–7].
Fibrinogen plays a critical role in clot strength and bleeding
[8–10]. Fibrinogen concentrate human (FCH) supplementation
reduces bleeding and the need for ABP transfusion in cardiovas-
cular surgery [11–14] and other settings [15–19]. In the United
States, FCH is not licensed for treatment of bleeding in patients
undergoing cardiovascular surgery who do not have congenital
fibrinogen deficiency.
A recent multinational, randomized clinical trial, REPLACE, un-
expectedly found that FCH treatment led to increased ABP trans-
fusions among patients undergoing complex cardiovascular
surgery [20]. The study design was based on a successful phase II,
single-centre study [12]. The safety-related results were consistent
with results from previous studies; percentages of patients with
adverse events were similar in both study groups, and thrombo-
embolic event rates were similar in patients receiving FCH versus
placebo. Owing to these safety results and the fact that no new
safety concerns were identified, it was deemed that rapid infu-
sion of FCH was well-tolerated.
Randomized clinical trials in perioperative bleeding are notori-
ously difficult to perform. Adherence to transfusion algorithms
used to standardize bleeding management across centres, surgi-
cal preference and several other variables may influence out-
comes despite randomization.
This paper reports secondary analyses of REPLACE. The objec-
tive was to identify possible reasons for the finding that FCH was
associated with an increase in transfusions of ABP.
MATERIALS AND METHODS
The methods used in the REPLACE trial have been published pre-
viously [20]. It was a phase III, prospective, multinational,
multicentre, randomized, double-blind, placebo-controlled study
(NCT01475669; EudraCT trial no. 2011-002685-20) conducted
between 23 January 2012 and 11 September 2014. The study
followed International Conference on Harmonization Good
Clinical Practice guidelines and approval was obtained from the
ethics committee or institutional review board at each centre.
Signed informed consent was obtained from patients before
participation.
Patients eligible for inclusion were those undergoing elective
open surgical procedures on any part of the aorta requiring car-
diopulmonary bypass (CPB) (including left heart bypass, with/
without other cardiac procedures, e.g. valve replacement/repair,
coronary artery bypass grafting), provided they demonstrated a
5-min bleeding mass (5-min BM) of 60–250 g. Exclusion criteria
included patients undergoing emergency aortic repair surgery,
reoperative aortic surgery at the same anatomical site as the orig-
inal procedure (e.g. replacement of a previously placed aortic
graft; resternotomy and rethoracotomy were permitted), patients
undergoing operation for infection and patients with congenital
or acquired coagulation disorders.
FCH (RiaSTAPV
R
, CSL Behring, Marburg, Germany) or placebo
was administered if a 5-min BM of 60–250 g was observed after
cessation of CPB, administration of protamine and establishment
of surgical haemostasis. A standardized transfusion algorithm was
followed if a 5-min BM after study medication was >_60 g, with
first-round administration of platelets (if platelet count
<100 103/ml; dose, 1 U) or fresh-frozen plasma (FFP; dose, 4 U)
and second-round administration of FFP or platelets (whichever
was not administered previously) (Fig. 1). In patients with persis-
tent bleeding, further treatment comprised 2 U FFP and 1 U pla-
telets. Red blood cells were administered to patients with
haemoglobin <7 g/dl, end-organ ischaemia, acute blood loss, or
other patient-specific conditions. Further treatment with FFP and
platelets was given as required until the 5-min BM was <60 g.
The primary end point was the total number of units of all
ABPs (FFP, platelets, red blood cells) given during the first 24 h af-
ter administration of the study medication. Secondary end points
included a second 5-min BM (after study medication administra-
tion) and a difference between the first and second 5-min BM.
The unexpected study outcome was explored using post hoc
analyses by stratifying results in 3 ways. Firstly, patients from the
intent-to-treat population whose treatment was fully compliant
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with the transfusion algorithm were defined as ‘completers’ of
the transfusion algorithm (CTA patients). Patients not treated
according to the algorithm were classified as non-CTA. The sec-
ond stratification was by pretreatment fibrinogen level, 20 min
before cessation of CPB (<_2 g/l or >2 g/l; 2 g/l threshold was cho-
sen because international guidelines on bleeding recommend fi-
brinogen supplementation when fibrinogen levels are <2 g/l [21,
22]). Thirdly, patients were stratified according to whether they
were among the first 3 to be treated at their study centre (‘early’
patients), to account for potential errors as the staff at the sites
became familiar with the protocol. The original intention was to
include 6–8 sites; because of lower-than-expected recruitment,
more sites were added and multiple sites were pooled for rank-
sum score analysis.
Differences between CTA and non-CTA patients were analysed
using Fisher’s exact test. All other statistical analyses were per-
formed using the Wilcoxon rank sum score test.
Given the disparity in results between the phase II study and
the phase III REPLACE study, a narrative comparison of patient
demographics at entry (including surgical procedure undertaken
and baseline fibrinogen) and the timing of the first and second
bleeding mass [mean, standard deviation (SD)] was performed.
Implications of quantitative and qualitative differences between
the study cohorts are discussed, and conclusions regarding the
influence of these factors on final study results are based on au-
thor expert opinion.
RESULTS
In total, 152 patients received treatment (FCH, n = 78; placebo,
n = 74) and 142 completed the study. Baseline characteristics
were similar across both groups: mean age, 64 years; mean body
mass index, 26 kg/m2; the mean Transfusion Risk Understanding
Scoring Tool score was 2 in both groups. Surgery involved repair
of a thoracic aortic aneurysm in most patients (FCH, 96%; pla-
cebo, 95%). Mean plasma fibrinogen levels before surgery were
comparable (FCH, 3.03 g/l; placebo, 3.06 g/l), but the median first
5-min BM was higher in the FCH group [FCH, 107.0 g (interquar-
tile range 76.0–138.0 g); placebo, 91.0 g (71.0–112.0 g)]. Although
not significant, the decrease in the 5-min BM needed to meet
the criterion for stopping treatment (<60 g) was numerically 50%
greater in the FCH group than in the placebo group (i.e. from the
pretreatment median value, reductions of 48 g and 32 g were
needed for stopping treatment in the FCH and placebo groups,
respectively).
Figure 1: Study protocol—sequence of treatments to control bleeding during REPLACE. aFresh-frozen plasma and/or platelets to be administered according to stan-
dard treatment regimen. bRepeat cycle of 5-min bleeding mass and standard treatment regimen until bleeding is controlled. CPB: cardiopulmonary bypass; IMP: in-
vestigational medicinal product.
Table 1: Transfusion of allogeneic blood products and 5-min BM measurements according to adherence to transfusion algorithm
ITT CTA Non-CTA
FCH
(N = 78)
PBO
(N = 74)
FCH
(N = 47)
PBO
(N = 57)
FCH
(N = 31)
PBO
(N = 17)
Allogeneic blood products, 24 h (median units transfused) 5.0* 3.0 3.0** 1.0** 11.0 9.0
First 5-min BM (g), median 107.0 91.0 100.0 85.0 107.0 98.0
Difference between FCH and PBO in median first 5-min BM (g) 16.0 15.0 9.0
Second 5-min BM (g), median 78.0 72.0 67.0 64.0 87.0 78.0
Difference between FCH and PBO in median second 5-min BM (g) 6.0 3.0 9.0
Change in 5-min BM (second – first measurement) (g), median -20.0 -19.5 -21.0 -19.0 -8.0 -21.0
Difference between FCH and PBO in median 5-min BM reduction (g) -0.5 -2.0 13.0
*P < 0.05 vs placebo.
**P < 0.001 vs non-completers.
5-min BM: 5-min bleeding mass; CTA: patients whose treatment was adherent with transfusion algorithm; FCH: fibrinogen concentrate human; ITT: intent-to-
treat; non-CTA: patients whose treatment was not fully adherent with the transfusion algorithm; PBO: placebo.
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The transfusion algorithm was adhered to in 104 patients
(68.4%; CTA) and not adhered to in 48 patients (31.6%; non-CTA).
In the FCH group, 31 patients were non-CTA (39.7%) including 7
reoperations, vs 17 (23.0%) in the placebo group with 3 reopera-
tions. The difference between the 2 treatment groups in the
CTA:non-CTA ratio was statistically significant (P = 0.036). Before
administration of the study medication, 102 patients (69.4%) had
plasma fibrinogen levels <_2 g/l, and 45 (30.6%) >2 g/l. Seventy-
one patients (46.7%) were ‘early’ patients at their study centre.
Significantly larger quantities of ABPs were given to non-CTA
versus CTA patients (P < 0.001; Table 1), regardless of treatment.
The median number of units transfused was higher with FCH
than with placebo regardless of transfusion algorithm adherence.
The first 5-min BM was higher in the FCH group than in the pla-
cebo group for intent-to-treat and CTA populations, but similar
for non-CTA patients. A slightly greater median reduction in 5-
min BM was observed with FCH versus placebo among CTA but
not non-CTA patients.
Table 2 shows outcomes by pretreatment fibrinogen level and
adherence to the transfusion algorithm. A numerically lower sec-
ond 5-min BM with FCH versus placebo was seen only in CTA
patients with a pretreatment plasma fibrinogen level <_2 g/l; this
was despite the median first 5-min BM being 22.5 g greater in
the FCH group. In this group, median reduction in 5-min BM
was 24.0 g with FCH and 15.5 g with placebo (P = 0.071). In con-
trast, FCH did not show efficacy benefits in CTA patients with
pretreatment fibrinogen >2 g/l. The results in non-CTA patients
were inconsistent. In all subgroups defined according to pretreat-
ment fibrinogen level, ABP transfusion was numerically higher
with FCH versus placebo.
As shown previously, there was considerable variation across
pooled study centres for ABP transfusion and treatment protocol
adherence. Adherence rates were higher in the Czech Republic
(100%) and Japan (87.5%) versus those in other pooled centres
(43–58%). Among the CTA patients, the largest differences be-
tween FCH and placebo in ABP transfusion were observed in the
UK and the Czech Republic (FCH versus placebo: 4 vs 0 units
transfused; Fig. 2). Correspondingly, these centres showed the
largest differences between FCH and placebo in first 5-min BM
(35 ml and 55 ml greater with FCH versus placebo in the UK and
the Czech Republic, respectively). The reduction in the 5-min BM
was larger with FCH versus placebo in CTA patients at 4/5 pooled
centres (Fig. 2).
In ‘early’ patients, adherence to the transfusion algorithm was
lower than in ‘late’ patients [62% (FCH 18/36, placebo 26/35) vs
74% (FCH 29/42; placebo 31/39); Table 3]. ‘Early’ FCH-treated
patients had significantly higher first 5-min BM and ABP con-
sumption than ‘early’ placebo patients, whereas BM reduction
was similar between the study arms. ‘Late’ patients showed simi-
lar first 5-min BM and ABP consumption in the FCH and placebo
groups, but a trend towards greater reduction of bleeding was
observed in the FCH group. This trend became more pro-
nounced when we considered the subsets of CTA patients and
CTA patients with pretreatment fibrinogen levels <_2 g/l, although
statistical significance was not reached. Furthermore, in ‘late’ CTA
patients with pretreatment fibrinogen <_2 g/l, median ABP transfu-
sion was numerically lower with FCH versus placebo (2 vs 4 units;
P = 0.573).
Comparisons of REPLACE with the preceding phase II study
are explored in Table 4 and Fig. 3. Distributions by surgical pro-
cedure show that comparable percentages of patients underwent
thoracic aortic aneurysm repair with or without proximal arch
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Figure 2: Results by pooled centres among patients whose treatment was adherent with the transfusion algorithm: first 5-min bleeding mass (5-min BM) (A); transfu-
sion of allogeneic blood products over 24 h (B); median change in 5-min BM in response to study medication (second versus first 5-min BM) (C). FCH: fibrinogen con-
centrate human.
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and thoracoabdominal aortic aneurysm repair in the phase II
study, whereas in REPLACE only a small percentage of patients
underwent thoracoabdominal aortic aneurysm repair. Mean
plasma fibrinogen levels before administration of the study medi-
cation were higher in REPLACE than in the phase II study; more-
over, the percentage of patients with pretreatment fibrinogen
levels >2 g/l was 3 times higher in REPLACE than in the phase II
study. The percentage of randomized patients not meeting
bleeding criteria for study inclusion was higher in REPLACE than
in the phase II study. In REPLACE, 327 randomized patients (63%)
exhibited 5-min BM <60 g vs 6 (7.5%) in the phase II study.
A 51% reduction in 5-min BM was seen with FCH in the phase II
study and only a 9% reduction with placebo. In comparison, a
smaller reduction with FCH and a larger reduction with placebo
was observed in REPLACE. The mean time from CPB cessation to
the first 5-min BM was prolonged in REPLACE: 25.6 min (SD:
13.5 min) vs 11.3 min (SD: 7.9 min) in the phase II study (Fig. 3).
The time between the end of the first and start of the second
5-min BM measurement was also prolonged in REPLACE.
DISCUSSION
REPLACE study results demonstrated a lack of efficacy benefit
with FCH [20]. The current analyses show that the difference be-
tween the REPLACE results and those from the preceding phase
II study, which reported efficacy benefits, may have been due to
unavoidable differences in the study population, variation in FCH
administration, and variation in adherence to the transfusion
protocol.
Because pretreatment plasma fibrinogen levels >2 g/l were
seen in 7% of patients in the phase II trial, it was assumed that
few REPLACE participants would meet this criterion; however,
31% did, potentially limiting the FCH treatment effect. The results
presented here support the hypothesis that FCH may be more ef-
fective in patients with plasma fibrinogen <_2 g/l vs >2 g/l. FCH is
licensed in Europe for use in acquired coagulation deficiencies
with hypofibrinogenaemia [23], and fibrinogen supplementation
is recommended for plasma fibrinogen levels <1.5–2 g/l [21, 24].
Due to reanalysis and inclusion of reoperations, the numbers
of CTA and non-CTA patients differ slightly from those in the pri-
mary publication. Non-adherence to the transfusion algorithm
may have increased data variability and decreased the likelihood
of observing the true treatment effect of FCH. The percentage of
non-CTA patients in the FCH group was higher than with placebo
(40% vs 23%), which had a major impact on the rank-sum score.
Also, adherence to the transfusion algorithm increased among
‘late’ versus ‘early’ patients. Because the effects of FCH were more
evident in ‘late’ patients, investigators who treated more patients
likely gained familiarity and proficiency with the protocol, en-
abling more accurate assessment of the FCH treatment effect.
The protocol’s complexity and the introduction of a study-
specific transfusion algorithm led to increased deviations in ‘early’
patients. Also, at the start of the study, investigators may have
had low confidence in the level of patient care provided by the
protocol, leading to possible selection of more ‘straightforward’
patients (this could explain the high baseline fibrinogen levels in
REPLACE versus the phase II study). Had the number of centres
been 6–8 as planned, 18–24 ‘early’ patients and 130 ‘late’
patients would have been enrolled. The larger number of study
centres meant fewer patients were enrolled at each site, resulting
in 71 ‘early’ and 81 ‘late’ patients, which affected the data analysis.
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With a greater number of patients at each site as originally
planned, a complete rank sum per study site would have been
possible. However, with an average of 4.6 patients per site, multi-
ple sites had to be pooled for the analysis. With numerous causes
of variability among the sites, the feasibility of a rank-sum score
including several sites may be questioned. Future trials would
likely benefit from reduced variability, either by increasing the
numbers of patients included from each site (thus reducing the
number of ‘early’ patients included) or reducing the number of
sites used. However, the challenge of enrolling a sufficient
number of patients using either of these options may mean that
reducing this variability is not feasible.
Individually, none of the 3 patient stratifications explored pro-
vided a clear explanation for the REPLACE results. However,
when considering adherence to the algorithm, baseline fibrino-
gen level, and previous study centre experience together, trends
in favour of FCH were observed. This finding is not statistically
robust due to the small number of patients meeting all 3 criteria.
Potentially, a larger study would enable more definite conclu-
sions to be drawn, as would changes in design to improve
Table 4: Comparison of results of the REPLACE trial with those from the preceding phase II study
REPLACE Preceding phase II study
FCH Placebo Total FCH Placebo Total
Surgery type, N (%)
TAA- 43 (55) 34 (46) 77 (51) 9 (31) 12 (38) 21 (34)
TAAA 3 (4) 4 (5) 7 (5) 8 (28) 10 (31) 18 (30)
TAA+ 32 (41) 36 (49) 68 (45) 12 (41) 10 (31) 22 (36)
Pretreatment plasma fibrinogen level (assessed at end of CPB)
Mean (g/l) 1.80 1.73 1.57 1.56
<_2 g/l, N (%) 51 (67) 51 (72) 102 (69) 26 (90) 30 (97) 57 (93)
>2 g/l, N (%) 25 (33) 20 (28) 45 (31) 3 (10) 1 (3) 4 (7)
Randomized patients (%) not meeting bleeding criteria for study
inclusion
322/519 (62) 15/80 (19)
Difference between median first and median second 5-min BMa 29 (27%
reduction)
19 (21%
reduction)
52 (51%
reduction)
10 (9%
reduction)
aDifferences between median values (as opposed to median changes, which are shown elsewhere) are provided here because the latter data are not available for
the phase II study.
5-min BM: 5-min bleeding mass; CPB: cardiopulmonary bypass; FCH: fibrinogen concentrate human; TAA: thoracic aortic aneurysm; TAAA: thoracoabdominal
aortic aneurysm.
Figure 3: First and second bleeding mass: comparison with the preceding phase II study in relation to timing (mean, SD). BM: bleeding mass; CPB: cardiopulmonary
bypass; SD: standard deviation.
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adherence and target treatment of patients with low fibrinogen
concentration.
The imbalance in pretreatment 5-min BM between the FCH
and placebo groups may also have affected the REPLACE results.
The median reduction needed to end the intraoperative transfu-
sion regimen was 50% higher in the FCH arm. Study centres with
the largest differences in first 5-min BM between the FCH and
placebo groups showed the greatest disparities between the 2
arms in quantity of ABPs transfused; this imbalance in the 5-min
BM is attributable to chance.
Efficacy benefits with FCH were observed in the preceding
phase II study [12]; therefore, differences between it and
REPLACE may be important. The extended time between CPB
cessation and the first 5-min BM in REPLACE increased the op-
portunity for surgical haemostasis. In contrast, the 5-min BM as-
sessment in the phase II study had been practised beforehand.
There were also differences in patients’ characteristics: in
REPLACE, few patients underwent thoracoabdominal aortic an-
eurysm repair (a procedure associated with relatively high rates
of ABP transfusions) and pretreatment fibrinogen levels were
high. The high percentage of randomized patients not bleeding
sufficiently in REPLACE versus in the phase II study indicates
study population differences. Also, the algorithm-defined admin-
istration of ABPs differed between the studies.
Procedural differences between REPLACE and clinical practice
may also be relevant. Fibrinogen was administered at a relatively
high single dose in REPLACE. In clinical practice, initial treatment
typically comprises a lower initial dose with the potential for fur-
ther adjunctive treatment depending on clinical need and mea-
surement of fibrinogen levels or fibrin-based clot strength. The
low bleeding rates observed in REPLACE do not reflect those ob-
served in routine clinical practice [25, 26], where 5-min BM is
rarely used and prethawed plasma and platelets are not routinely
available in the operating room (in REPLACE, prethawed ABPs
were available to minimize delay of haemostatic therapy in the
placebo arm).
Limitations
The limited number of patients in the original trial introduced
the potential for a type II error in the subsequent primary analy-
sis. The present analyses have some limitations. Firstly, the origi-
nal study was not powered for the smaller numbers of patients in
the subgroup analyses. Secondly, the subgroups were based on
arbitrary definitions. Non-CTA patients are a disparate group;
some required reoperation and the algorithm was deliberately
abandoned in others. Also, different cut-off points for pretreat-
ment fibrinogen levels and numbers of patients previously
treated at each site could have been chosen. Nevertheless, the
present data are helpful in understanding the REPLACE results.
CONCLUSION
In conclusion, REPLACE study outcomes may have been influ-
enced by adherence to the transfusion algorithm, patients’ pre-
treatment fibrinogen levels and investigators’ familiarity with
implementing the protocol. There were also several important
differences between the multicentre REPLACE study and the pre-
ceding single-centre phase II study, which reported efficacy
benefits with FCH versus placebo. Together, this variability might
explain the differences in results with regards to ABPs between
the phase II and REPLACE studies and may help inform the de-
sign of future studies of FCH in patients undergoing cardiac
surgery.
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